2
Orphan Designations
0 approved, 2 designated
2
FDA Approvals
Latest: MIPLYFFA (2024)
0
Active Trials
2
Rare Diseases
across 5 areas
0
News (30d)
Quiet
Acer Therapeutics Inc. is a company with 2 orphan drug designations across 2 rare diseases, including 2 FDA-approved therapies.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Ehlers-Danlos syndrome | celiprolol | Des.TrialAppr. |
| maple syrup urine disease | sodium phenylbutyrate | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio